Reversal of the novel oral anticoagulants dabigatran, rivoraxaban, and apixaban

Current Opinion in Critical Care

Volumn 21, Issue 2, 2015, Pages 127-133

  Liotta, Eric M ^a   Levasseur Franklin, Kimberly E ^b   Naidech, Andrew M ^a  

^a Department of Neurology ^*  (United States)

^b NORTHWESTERN UNIVERSITY   (United States)

Author keywords

direct factor Xa inhibitors; direct thrombin inhibitor; hemorrhage; hemostasis; intracerebral hemorrhage

Indexed keywords

ANTICOAGULANT AGENT; APIXABAN; DABIGATRAN; HEMOSTATIC AGENT; RIVAROXABAN; WARFARIN; ANTIDOTE; ANTITHROMBIN; BENZIMIDAZOLE DERIVATIVE; BETA ALANINE; BLOOD CLOTTING FACTOR 10A INHIBITOR; COAGULATING AGENT; FIBRINOLYTIC AGENT; MORPHOLINE DERIVATIVE; PYRAZOLE DERIVATIVE; PYRIDONE DERIVATIVE; THIOPHENE DERIVATIVE;

ANTICOAGULANT THERAPY; BLEEDING; CREATININE CLEARANCE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG ELIMINATION; DRUG EXCRETION; DRUG HALF LIFE; HUMAN; NONHUMAN; PHASE 3 CLINICAL TRIAL (TOPIC); REVIEW; URINARY EXCRETION; ANALOGS AND DERIVATIVES; ANIMAL; ANIMAL MODEL; HEMORRHAGE; THROMBOEMBOLISM;

ANIMALS; ANTIDOTES; ANTITHROMBINS; BENZIMIDAZOLES; BETA-ALANINE; COAGULANTS; FACTOR XA INHIBITORS; FIBRINOLYTIC AGENTS; HEMORRHAGE; HUMANS; MODELS, ANIMAL; MORPHOLINES; PYRAZOLES; PYRIDONES; THIOPHENES; THROMBOEMBOLISM;

EID: 84926378769     PISSN: 10705295     EISSN: 15317072     Source Type: Journal    
DOI: 10.1097/MCC.0000000000000181     Document Type: Review

References (23)

1. Liotta EM, Prabhakaran S. Warfarin-Associated intracerebral hemorrhage is increasing in prevalence in the United States. J Stroke Cerebrovasc Dis 2013; 22:1151-1155
2. Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009; 361:1139-1151
3. Patel MR, Mahaffey KW, Garg J, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 2011; 365:883-891
4. Granger CB, Alexander JH, McMurray JJV, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2011; 365:981-992
5. Holbrook A, Schulman S, Witt DM, et al. Evidence-based management of anticoagulant therapy: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest 2012; 141 (2 Suppl):e152S-e184S
6. Sarode R, Milling TJ, Refaai MA, et al. Efficacy and safety of a 4-factor prothrombin complex concentrate in patients on vitamin K antagonists presenting with major bleeding: a randomized, plasma-controlled phase IIIb study. Circulation 2013; 128:1234-1243
7. Van Ryn J, Stangier J, Haertter S, et al. Dabigatran etexilate-A novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity. Thromb Haemost 2010; 103:1116-1127
8. Garcia D, Barrett YC, Ramacciotti E, Weitz JI. Laboratory assessment of the anticoagulant effects of the next generation of oral anticoagulants. J Thromb Haemost 2013; 11:245-252
9. Wang X, Mondal S, Wang J, et al. Effect of activated charcoal on apixaban pharmacokinetics in healthy subjects. Am J Cardiovasc Drugs 2014; 14:147-154
10. Levy JH, Faraoni D, Spring JL, et al. Managing new oral anticoagulants in the perioperative and intensive care unit setting. Anesthesiology 2013; 118:1466-1474
11. Boehringer Ingelheim Pharmaceuticals, Inc. (2012). Pradaxa (Dabigatran Etexilate Mesylate) Prescribing Information. http://www.pradaxa.com. [Accessed 24 September 2014]
12. Huttner HB, Schellinger PD, Hartmann M, et al. Hematoma growth and outcome in treated neurocritical care patients with intracerebral hemorrhage related to oral anticoagulant therapy: comparison of acute treatment strategies using vitamin k, fresh frozen plasma, and prothrombin complex concentrates. Stroke 2006; 37:1465-1470
13. Liotta EM, Garg RK, Temes RE, et al. Warfarin-Associated intracerebral hemorrhage is inadequately treated at Community Emergency Departments. Stroke 2012; 43:2503-2505
14. Lu G, DeGuzman FR, Hollenbach SJ, et al. A specific antidote for reversal of anticoagulation by direct and indirect inhibitors of coagulation factor Xa. Nat Med 2013; 19:446-451
15. Schiele F, Van Ryn J, Canada K, et al. A specific antidote for dabigatran: functional and structural characterization. Blood 2013; 121:3554-3562
16. Zhou W, Schwarting S, Illanes S, et al. Hemostatic therapy in experimental intracerebral hemorrhage associated with the direct thrombin inhibitor dabigatran. Stroke 2011; 42:3594-3599
17. Pragst I, Zeitler SH, Doerr B, et al. Reversal of dabigatran anticoagulation by prothrombin complex concentrate (Beriplex P/N) in a rabbit model. J Thromb Haemost 2012; 10:1841-1848
18. Grottke O, Van Ryn J, Spronk HMH, Rossaint R. Prothrombin complex concentrates and a specific antidote to dabigatran are effective ex-vivo in reversing the effects of dabigatran in an anticoagulation/liver trauma experimental model. Crit Care 2014; 18:R27
19. Eerenberg ES, Kamphuisen PW, Sijpkens MK, et al. Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate: a randomized, placebocontrolled, crossover study in healthy subjects. Circulation 2011; 124:1573-1579
20. Levi M, Moore KT, Castillejos CF, et al. Comparison of three-factor and fourfactor prothrombin complex concentrates regarding reversal of the anticoagulant effects of rivaroxaban in healthy volunteers. J Thromb Haemost 2014; 12:1-9
21. Zhou W, Zorn M, Nawroth P, et al. Hemostatic therapy in experimental intracerebral hemorrhage associated with rivaroxaban. Stroke 2013; 44:771-778
22. Hickey M, Gatien M, Taljaard M, et al. Outcomes of urgent warfarin reversal with frozen plasma versus prothrombin complex concentrate in the Emergency Department. Circulation 2013; 128:360-364
23. Sorensen B, Spahn DR, Innerhofer P, et al. Clinical review: prothrombin complex concentrates-evaluation of safety and thrombogenicity. Crit Care 2011; 15:201